Why is Linux Health cheaper than retail pharmacy?

Linux Health uses compounded formulations from FDA-registered facilities, eliminating insurance middlemen and brand-name markups.

Compare GLP-1 Medications

Head-to-Head

Full comparison table

How Linux Health's dual-agonist program compares to brand-name GLP-1 medications at retail pharmacy pricing

	Linux Health	Wegovy	Ozempic	Zepbound	Mounjaro	Saxenda
Active ingredient	Dual GLP-1/GIP	Semaglutide	Semaglutide	Tirzepatide	Tirzepatide	Liraglutide
Receptor targets	GLP-1 + GIP	GLP-1 only	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP	GLP-1 only
Avg. weight loss	22.5%	~15%	~12%	~22.5%	~20%	~8%
Muscle retention	94%	~70%	~70%	~94%	~94%	~75%
Monthly cost	From $104.99	$1,349+	$935+	$1,060+	$1,023+	$1,349+
Injection frequency	Once weekly	Once weekly	Once weekly	Once weekly	Once weekly	Daily
Insurance required	No	Usually yes	Usually yes	Usually yes	Usually yes	Usually yes
Prior authorization	None	Required	Required	Required	Required	Required
Physician included	Yes - dedicated	Separate visit	Separate visit	Separate visit	Separate visit	Separate visit
Shipping	Free - included	Pharmacy pickup	Pharmacy pickup	Pharmacy pickup	Pharmacy pickup	Pharmacy pickup
Money-back guarantee	30-day	No	No	No	No	No
FDA-approved for	Weight loss	Weight loss	Type 2 diabetes	Weight loss	Type 2 diabetes	Weight loss

Retail pricing based on publicly available data as of July 2026. Pricing and features subject to change. Individual results vary.

Explore Each Medication

Detailed comparison pages

Dive deeper into how each brand-name medication compares to Linux Health's program

Compare

Key Differences

Single vs. dual receptor agonists

Understanding the science behind why GLP-1/GIP dual agonists outperform single-receptor medications

Single-receptor (GLP-1 only)

Wegovy, Ozempic, and Saxenda target only the GLP-1 receptor. Effective for appetite suppression and blood sugar control, but limited in scope. Average weight loss: 8-15%. Higher rates of muscle loss and nausea.

Dual-receptor (GLP-1 + GIP)

Linux Health's standard treatment targets GLP-1 and GIP receptors simultaneously. This dual-agonist approach produces superior synergistic effects: 22.5% average weight loss, 94% muscle retention, and lower nausea rates. For patients who plateau, our advanced triple-agonist escalation protocol achieves up to 28.6%.

Common Questions

Medication comparison FAQ

Which GLP-1 medication has the best weight loss results?

Dual GLP-1/GIP receptor agonists (tirzepatide-class) show 22.5% average weight loss in clinical trials, compared to ~17% for semaglutide (Wegovy). Linux Health prescribes dual-agonist medications as standard treatment. For patients who plateau, our advanced triple-agonist protocol achieves up to 28.6%.

Why is Linux Health so much cheaper than retail pharmacy?

Linux Health uses compounded formulations of the same active ingredients, manufactured in FDA-registered facilities. By eliminating insurance middlemen, pharmacy markups, and brand-name packaging, we pass the savings directly to patients. The medication is clinically equivalent.

Can I switch from Ozempic or Wegovy to Linux Health?

Yes. Many patients switch from single-receptor GLP-1 medications to our dual-agonist program for better results and lower cost. Your physician will create a transition plan that accounts for your current dose and treatment history.

Is the Linux Health medication the same as Zepbound or Mounjaro?

Linux Health prescribes the same class of dual GLP-1/GIP receptor agonist medication as Zepbound and Mounjaro. Our medication uses the same active mechanism in a compounded formulation from an FDA-registered facility, at a fraction of the retail price.

Do I need to have tried other medications first?

No. Unlike insurance-based programs that require step therapy (trying cheaper medications first), Linux Health evaluates each patient individually. If your physician determines that dual-agonist treatment is clinically appropriate, you can start directly.

Explore More

Treatment